GEM ZIPCLIP

K242541 · Synovis Micro Companies Alliance A Subsidiary of Baxter Int · FZP · Jan 15, 2025 · General, Plastic Surgery

Device Facts

• Record ID: K242541
• Device Name: GEM ZIPCLIP
• Applicant: Synovis Micro Companies Alliance A Subsidiary of Baxter Int
• Product Code: FZP · General, Plastic Surgery
• Decision Date: Jan 15, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4300
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

ZIPCLIP is indicated for use in surgical procedures to occlude blood vessels.

Device Story

GEM ZIPCLIP is a sterile, single-use, pre-loaded mechanical applier containing 15 Grade 1 titanium microclips. Used in operating rooms by surgeons to occlude blood vessels. Device features scissor-like handles; manual compression drives distal jaws to close and deploy a clip around a vessel. Upon handle release, the device automatically loads the next clip into the jaws. Once all 15 clips are deployed, a gold-colored lockout clip prevents further jaw closure. The device is disposed of after use. By providing a combined applier and clip system, it simplifies the ligation process compared to systems requiring separate loading tools. The titanium clips remain as permanent implants. Clinical benefit is the reliable, efficient mechanical occlusion of blood vessels during surgery.

Clinical Evidence

No clinical data. Bench testing only. Testing included verification of reliable clip deployment, vessel ligation efficacy using simulated vessel models, and validation of MR-Conditional labeling.

Technological Characteristics

Mechanical assembly of plastic and metal components. Clips: Grade 1 titanium. Form factor: Pre-loaded, single-use, disposable applier with 15-clip capacity. Principle: Manual scissor-handle actuation for clip closure and automatic reload. Sterilization: Sterile. Connectivity: None.

Indications for Use

Indicated for use in surgical procedures to occlude blood vessels in patients requiring vessel ligation.

Regulatory Classification

Identification

An implantable clip is a clip-like device intended to connect internal tissues to aid healing. It is not absorbable.

Predicate Devices

• Vitalitec Titanium Hemostatic Clip (K981645)

Reference Devices

• Covidien Premium SurgiClip III (K142869)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo for the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo in blue. The word "ADMINISTRATION" is written below "U.S. FOOD & DRUG".

January 15, 2025

Synovis Micro Companies Alliance Julie Carlston Senior Manager, Regulatory Affairs 439 Industrial Lane Birmingham, Alabama 35211

Re: K242541

Trade/Device Name: Gem Zipclip Regulation Number: 21 CFR 878.4300 Regulation Name: Implantable Clip Regulatory Class: Class II Product Code: FZP Dated: December 18, 2024 Received: December 18, 2024

### Dear Julie Carlston:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory

{2}------------------------------------------------

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Digitally signed by Tek N. Tek N. Lamichhane -S Lamichhane -S 32-11-19-05:01:15 22:11:19 -05'00' Tek N. Lamichhane, Ph.D. Assistant Director DHT4B: Division of Plastic and Reconstructive Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

### Indications for Use

Indications for use

Submission Number (if known)

K242541

Device Name

GEM ZIPCLIP

Indications for Use (Describe)

ZIPCLIP is indicated for use in surgical procedures to occlude blood vessels.

Type of Use (Select one or both, as applicable)

> Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

| 510(k) #: | K242541 | 510(k) Summary | Prepared on: 2025-01-15 |
|-----------|---------|----------------|-------------------------|
|-----------|---------|----------------|-------------------------|

| Contact Details | 21 CFR 807.92(a)(1) |
|-----------------|---------------------|
|-----------------|---------------------|

| Applicant Name | Synovis Micro Companies Alliance |
|-----------------------------|-------------------------------------------------------|
| Applicant Address | 439 Industrial Lane Birmingham AL 35211 United States |
| Applicant Contact Telephone | [phone] |
| Applicant Contact | Mr. Daniel Davis |
| Applicant Contact Email | [e-mail] |

| Device Name | 21 CFR 807.92(a)(2) |
|-------------|---------------------|
|-------------|---------------------|

| Device Trade Name | GEM ZIPCLIP |
|---------------------|-------------------|
| Common Name | Implantable clip |
| Classification Name | Clip, Implantable |
| Regulation Number | 878.4300 |
| Product Code(s) | FZP |

| Legally Marketed Predicate Devices | 21 CFR 807.92(a)(3) |
|------------------------------------|---------------------|
|------------------------------------|---------------------|

| Predicate # | Predicate Trade Name (Primary Predicate is listed first) | Product Code |
|-------------|----------------------------------------------------------|--------------|
| K981645 | Vitalitec Titanium Hemostatic Clip | FZP |

| Device Description Summary | 21 CFR 807.92(a)(4) |
|----------------------------|---------------------|
|----------------------------|---------------------|

The GEM ZIPCLIP (ZIPCLIP) is a sterile, single-use automatic microclip applier. Each device contains 15 titanium microclips. When applied on a vessel, microclips remain with the patient as permanent implants. ZIPCLIP is for prescription use only and the use environment is the operating room.

The ZIPCLIP device is a pre-loaded, disposable, single-patient use mechanical assembly comprised of plastic and metal components. The applier device has (2) scissor-like handles that, when driven medially, close the distal jaws forming a closed clip the device in the open configuration. When released, the handles return to their resting state and the closed clip disengages from the applier. Simultaneously, a new clip is automatically loaded into the distal jaws for consecutive firing. When ZIPCLIP is empty a lockout clip (anodized gold in color) deploys between the jaws, preventing them from closing.

The ZIPCLIP is a mechanical assembly comprised of plastic and metal components. The clips are composed exclusively of titanium (Grade 1) and are supplied sterile in a preloaded channel that is incorporated into the number of clips per applier is fifteen (15). The clips are stacked and contained internal to the device. Clips cannot be reloaded once the stack is deployed and the applier is disposed of once emptied. Note, the ZIPCLIP preloaded microclips that can be used with the ZIPCLP device.

# Intended Use/Indications for Use

### 21 CFR 807.92(a)(5)

ZIPCLIP is indicated for use in surgical procedures to occlude blood vessels.

{5}------------------------------------------------

# Indications for Use Comparison

The ZIPCLIP is intended for blood vessel ligation Hemostatic Clip is intended for ligation of blood vessels. Although there are differences between the indication for use statements of the predicate and subject devices, the intended use (blood vessel ligation) is the same. Both devices are intended for ligation of blood vessels. The additional indication for use language of the predicate Titanium Hemostatic Clip is not necessary for indications for use as it goes beyond the general purpose of the device to include design aspects and specific use recommendations that are more appropriate to be covered in the instructions for use. Additionally, the subject ZIPCLIP indication for use wording is very similar to the reference device and automatic (preloaded clip appliers on the market. No new or different concerns are raised in terms of the subject device.

# Technological Comparison

## 21 CFR 807.92(a)(6)

21 CFR 807.92(a)(5)

Many characteristics of the predicate device and the subject device characteristics are the same. The subject device include the same basic microclip made out of identical base titanium material. The predicate and subject device a vessel using the same principle of operation via the use of a clip applier within the jaws and handles squeezed forming a closed clip.

Technological differences between the subject and predicate device were taken into consideration when determining substantial equivalence. The primary technological difference between the subject ZIPCLIP device and predicate Titanium Hemostatic Clip is that the ZIPCLIP device incorporates the microcip and clip applier together in one device and the predicate Titanium Hemostatic Clip requires the use of the separate clip applier. This difference does not introduce new questions of safety or efficacy as the final result of both devices is the same, a titanium microclip closed around the vessel. Performance testing shows that the ZIPCLIP microclip can be safely and effectively closed around vessels. Additionally, there are many devices on the market that combine clips and clip appliers into one device, such as the reference Covidien Premium SurgiClip III (K142869).

#### Non-Clinical and/or Clinical Tests Summary & Conclusions 21 CFR 807.92(b)

Baxter conducted bench testing a) to ensure safety and that it performs for its intended use: blood vessel ligation; and b) to demonstrate there are no new questions of safety or effectiveness compared to the predicate device.

Bench performance testing to verify that ZIPCLIP reliably deploys the clips and ligates vessels was performed. ZIPCLIP deployment of microclips on simulated vessels and microclip ligation of simulated vessels was performed using benchtop models to verify the ZIPCLIPs ability to safely and effectively occlude blood vessels. Additional testing was performed to verify the ZIPCLIP microclip is appropriate for MR-Conditional labeling and validate that ZIPCLIP is safe and effective for the intended user population.

Clinical Testing Not Applicable

Conclusion: The GEM ZIPCLIP is substantially equivalent to the predicate device Vitalitec Titanium Hemostatic Clip. The design/ technological differences were found to not affectiveness and are supported by design verification and validation activities performed. The non-clinical testing performed supports the subject device for its intended use.